To give a systematic overview on published decision-analytic studies and methodological approaches in the evaluation of therapies in Parkinson's disease (PD) and derive generic recommendations for future PD decision models. METHODS: A systematic literature review was performed to identify studies that evaluated interventions for PD using mathematical models. Using a standardized assessment form, information on methodological framework, results, limitations and conclusions were extracted from publications and reported in systematic evidence tables. The evidence on strengths and limitations was summarized in recommendations for further PD modeling. RESULTS: We identified 8 studies [1][2][3][4][5][6][7][8] that used mathematical models to evaluate the effect of different pharmaceutical and surgical treatment options in PD in different settings and countries. Modeling approaches comprised mathematical equations as well as decision-trees and Markov models with a time horizon ranging from 5 years to lifetime. All models based progression on the evolution of clinical surrogate endpoints and included economic consequences. No model is currently available that encompasses both the underlying biologic disease progression and the spectrum of all relevant complications, and in addition, links them to patient preferences as well as to economic outcomes. CONCLUSIONS: A generic and flexible decision model for PD, that can be applied to different treatment strategies should consider the entire spectrum of clinically relevant outcomes and complications during an adequately long time horizon and should be externally validated. Models for economic evaluations adoping a societal perspective should include patient preferences and all relevant economic consequences including those of adverse events. Evaluating early diagnosis in combination with neuroprotective therapies requires the use of health states that represent the natural history of the disease in untreated patients such as Hoehn & Yahr off stages or histologically defined health states. Cost-containment pressures worldwide are increasing the demand on drug developers to demonstrate the value of products in order to obtain reimbursement. To meet this demand, developers are turning to economic models. While models are informative tools, they can be expensive to produce, their complexity makes them difficult to understand and the lack of standardized formatting makes them hard to navigate. OBJECTIVE: To develop a low cost tool that allows model results to be viewed in a standard format and to increase interdisciplinary access models in order to support wider use in the development and marketing of new pharmaceuticals. METHODS: An electronic viewer (MODEL-IT) was developed as a "container" to display and run analyses of disease models. Building on the widespread familiarity of Windows © , the tool was programmed to work as a stand-alone application in a Win2000, WinXT, or WinNT environment. Screens were developed to display inputs and outcomes pertinent to the model being analyzed, while maintaining a consistent format. Incorporation of point and click technology was used to simplify model functions by programming buttons to carry out specific tasks. RESULTS: The MODEL-IT tool breaks input parameters into specific categories including drug efficacy, population characteristics and country-specific costs. All fields are editable. Outcomes are model-specific and include costs, survival and cost-effectiveness. Model edits can be saved for later use, printed and exported to other programs. To allow users access to detailed model information, the technical manual can be accessed through a button control. CONCLUSIONS: Current trends in the increased use of pharmacoeconomic analysis will demand standardization of models to streamline efficiency and transfer expertise to multidisciplinary users. Standardized user interfaces will become increasingly important in meeting these needs.
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THE USE OF A SEMI-MARKOV PROCESS MODEL IN COST-EFFECTIVENESS MODELING: THE CASE OF ANTI-EPILEPTIC DRUGS
Hawkins NS, Epstein D, Sculpher M University of York, York, North Yorkshire, United Kingdom OBJECTIVE: Markov models are often used as part of cost-effectiveness analysis to extrapolate from short-term experimental evidence. Most Markov models used in economic evaluation typically assume fixed transition probabilities with respect to time. This is because implementation of time-dependant probabilities for all states is difficult in widely used modeling software. This is a limiting assumption when transitions are clearly time dependent. In such circumstances, semi-Markov processes, with time-dependent probabilities, may be necessary to provide reliable estimates of cost-effectiveness. ME-THODS: The implementation of a semi-Markov process will be illustrated using a recent analysis of anti-epileptic drug sequences for the National Institute for Clinical Excellence. In this case study, the probability of treatment failure was dependant on the time spent on the current treatment. Although such models can be implemented in Excel or other modeling applications, the large number of states required makes this cumbersome. As an alternative, the model was realized using "R", a statistical
